It was found in this study that the serum T-PSA of treated patients in the combined group was significantly lower than that of the reference group (P < 0.001), indicating that the combined therapy could synergistically exert mutual promoting effects and further promote the apoptosis of cancer cells, thereby inhibiting the proliferation of cancer tissues and effectively reducing the content of serum markers, which have been proved in locally advanced prostate cancer [25]. This evidence concerns the gene KLK3 and Familial prostate cancer.